| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5fadc18369dac6778fe6217aed49ada7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4826
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4833
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4846
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4853
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6432
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-02 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04 |
| filingDate |
2008-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20dee52fd28a30315f03e4b907d5c057
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0965cc99395eb8e962cfd8b0ad05a156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9ce541b6af064222212faace8d17af4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e25e63e3a9177ed2be6fde6bcdc2b9c4 |
| publicationDate |
2020-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-PI0816837-A2 |
| titleOfInvention |
antidotes for factor xa inhibitors and methods for their use |
| abstract |
antidotes for factor xa inhibitors and methods for their use the present invention is related to antidotes for anticoagulants that target factor xa. antidotes are derived from the factor xa protein which bind to factor xa inhibitors and thus substantially neutralize them, but do not aggregate with the prothrombinase complex. the derivatives described herein are devoid of or have reduced intrinsic coagulant activity. disclosed here are methods of stopping or preventing bleeding in a patient undergoing anticoagulant therapy with a factor xa inhibitor. |
| priorityDate |
2007-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |